Zoetis Inc. (NYSE:ZTS) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analysts have a consensus “Hold” rating on Zoetis, with nine holds, eight buys and one sell among 18 brokerages. The average 12-month price target is $109.62, although several firms recently lowered their targets.
• Zoetis reported quarterly EPS of $1.87, slightly above expectations, but revenue of $2.47 billion declined 0.2% year over year. Full-year 2026 EPS guidance of $6.15–$6.25 has added to concerns about growth, competition and the company’s outlook.
• Shares opened at $75.23, near the lower end of their 52-week range, while Zoetis announced a quarterly dividend of $0.53, or $2.12 annualized, representing a 2.8% yield.

Zoetis Inc. (NYSE:ZTS - Get Free Report) has earned a consensus rating of "Hold" from the eighteen brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $109.6154.

A number of brokerages have commented on ZTS. UBS Group reduced their price objective on Zoetis from $85.00 to $80.00 and set a "neutral" rating on the stock in a research note on Friday, August 7th. Stifel Nicolaus lowered their target price on Zoetis from $95.00 to $85.00 and set a "hold" rating for the company in a research note on Friday, June 26th. HSBC dropped their target price on Zoetis from $140.00 to $95.00 and set a "buy" rating on the stock in a report on Monday, July 6th. William Blair reissued a "market perform" rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, BNP Paribas Exane decreased their price target on Zoetis from $146.00 to $110.00 and set an "outperform" rating for the company in a report on Tuesday.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Citigroup lowered its Zoetis price target from $112 to $96 but retained a Buy rating, implying substantial upside from recent levels. The continued Buy recommendation may provide support despite the more cautious valuation. Benzinga article
• Positive Sentiment: BNP Paribas Exane cut its target from $146 to $110 while maintaining an Outperform rating. The target still indicates significant potential appreciation, suggesting the firm views recent weakness as excessive relative to Zoetis’ long-term prospects. Tickerreport.com article
• Neutral Sentiment: JPMorgan reduced its Zoetis price target to $115, adding to the pattern of analysts recalibrating estimates without necessarily abandoning the investment case. JPMorgan price target article
• Neutral Sentiment: Piper Sandler lowered its target from $90 to $80 and assigned a Neutral rating. The target remains modestly above the recent share price, but the stance signals limited near-term conviction. Benzinga article
• Negative Sentiment: Recent coverage highlights leadership changes, competitive pressures and concerns surrounding Zoetis’ outlook. The company’s latest quarter also showed revenue down 0.2% year over year, while full-year 2026 EPS guidance of $6.15–$6.25 is below some analyst expectations, weighing on sentiment. ZTS Q2 Deep Dive article

Zoetis Stock Performance

Shares of ZTS stock opened at $75.23 on Wednesday. The company's fifty day simple moving average is $76.57 and its 200-day simple moving average is $99.89. Zoetis has a 52 week low of $71.45 and a 52 week high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market cap of $31.09 billion, a PE ratio of 12.39, a P/E/G ratio of 1.29 and a beta of 0.74.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the business posted $1.76 EPS. The business's quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts anticipate that Zoetis will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis's dividend payout ratio is 34.93%.

Institutional Investors Weigh In On Zoetis

A number of large investors have recently added to or reduced their stakes in ZTS. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Zoetis during the second quarter valued at about $25,000. Dunhill Financial LLC boosted its holdings in Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company's stock valued at $25,000 after purchasing an additional 296 shares during the last quarter. Prosperity Bancshares Inc acquired a new stake in Zoetis during the 4th quarter valued at approximately $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in Zoetis during the 1st quarter worth approximately $28,000. Finally, Root Financial Partners LLC raised its position in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source